Type 2 Diabetes Marks a Distinct Clinical and Serologic Pattern in Sjögren’s Disease
In a multicenter real-world analysis of Sjögren’s disease, type 2 diabetes mellitus clustered with a heavier cardiometabolic burden and a different autoimmune laboratory profile. Patients with diabetes carried more hypertension, hypercholesterolemia, hypertriglyceridemia, and higher body mass index than their non-diabetic comparators, while disease activity remained broadly similar between groups.
The signal was not limited to metabolism. After adjustment for age and disease duration, diabetes was associated with lower odds of anti-SSB/La positivity and low C3, suggesting a serologic pattern that may reflect less prominent B-cell activity or a different immunologic phenotype within Sjögren’s disease.
Metabolic Comorbidity and Autoimmune Phenotype Did Not Move in Parallel
The cohort included 245 patients, 95% of them female, with a mean age of 70 ± 12 years. One hundred had diabetes, and the comparison group consisted of age- and sex-matched non-diabetic patients. In a disease where fatigue, sicca symptoms, systemic inflammation, and extraglandular complications often overlap, the metabolic burden stood out as a separate axis of risk rather than a simple byproduct of age alone.
Hypertension, dyslipidemia, and excess weight are clinically familiar in type 2 diabetes, but their coexistence with Sjögren’s disease creates a more complicated bedside picture. Chronic metabolic stress can amplify vascular injury, increase endothelial dysfunction, and make it harder to disentangle autoimmune-driven morbidity from traditional cardiovascular risk. The study’s finding of similar disease activity across groups is important because it suggests the serologic differences were not just a reflection of more active systemic Sjögren’s disease in the diabetic cohort.
ESSDAI data were available for only 54% of patients, so any interpretation of inflammatory burden needs restraint. Still, within the data that were available, diabetes did not appear to track with higher measured disease activity. The more striking separation emerged in the laboratory profile, where anti-SSB/La and C3 were less common in the diabetic group after adjustment.
Lower Anti-SSB/La and C3 Point Toward a Different B-Cell Signature
The adjusted odds ratio for anti-SSB/La positivity in patients with diabetes was 0.48, with a 95% confidence interval of 0.25 to 0.88. Low C3 showed an even stronger inverse association, with an odds ratio of 0.30 and a 95% confidence interval of 0.10 to 0.76. Those estimates remained similar in conditional analyses that accounted for the matched design.
In practical terms, the data suggest that Sjögren’s disease with diabetes may be less enriched for the classic serologic markers that often accompany stronger B-cell activation. Anti-SSB/La positivity and complement consumption are not minor laboratory curiosities; they often help define immunologic subtypes and can shape how clinicians think about systemic autoimmunity. A diabetic patient with Sjögren’s disease may therefore present with a phenotype that is metabolically heavier but serologically quieter.
The finding should be treated as hypothesis-generating, not definitive. These associations were identified at nominal significance without correction for multiple testing, and the study design cannot establish whether diabetes biologically reshapes the autoimmune phenotype, whether a distinct Sjögren’s subgroup is more likely to develop diabetes, or whether shared age-related and metabolic pathways account for both patterns.
Cardiovascular History Tracked More Strongly With Age and Hypertension Than With Autoantibodies
Thirty-one patients had a history of cardiovascular events. In the primary Firth logistic model, fitted to 239 patients, age and hypertension were associated with cardiovascular history. Each additional year of age carried an odds ratio of 1.07, with a 95% confidence interval of 1.02 to 1.12 and a p value of 0.005. Hypertension showed an odds ratio of 3.21, with a 95% confidence interval of 1.27 to 9.54 and a p value of 0.012.
Anti-SSB/La, smoking, and current hydroxychloroquine use were not significantly associated with cardiovascular history in that model. Multiple-imputation results were consistent, which strengthens confidence that the age and hypertension signals were not artifacts of missing data handling. The cardiovascular analysis was exploratory, but it still reflects the way risk concentrates in older patients with long-standing vascular disease rather than in a single autoimmune marker.
One sentence captures the bedside implication: hypertension, not serology, emerged as the clearest cardiovascular discriminator.
Metformin Did Not Separate Itself as a Cardiovascular Modifier
Adjusted analyses of metformin exposure did not show statistically significant associations. On the surface, that may disappoint clinicians hoping for a pharmacologic lever that could link glycemic control to the autoimmune and cardiovascular dimensions of Sjögren’s disease. In reality, the negative result is unsurprising in a retrospective observational cohort where treatment indication, diabetes severity, duration of exposure, and concomitant medications can all blur any apparent drug effect.
The study does not support using metformin as a marker of lower cardiovascular burden in this population. Nor does it rule out any future role for glucose-lowering therapy in reshaping inflammatory risk. It simply shows that, within this dataset, metformin did not stand out after adjustment.
What Rheumatology and Endocrinology Clinicians Should Take From the Data
This analysis places type 2 diabetes mellitus in Sjögren’s disease at the intersection of metabolic risk and immune phenotype. The diabetic subgroup was older, more hypertensive, and more dyslipidemic, but it also showed fewer classic serologic features associated with B-cell activity. That combination matters because it may influence how clinicians interpret laboratory panels, cardiovascular risk, and the likelihood that a patient’s systemic profile reflects a familiar autoimmune pattern.
The study also exposes a familiar limitation in real-world rheumatology research: incomplete phenotyping. ESSDAI was missing in nearly half the cohort, and the cardiovascular analysis remained observational. Even so, the sample is useful because it reflects routine clinical practice rather than a narrowly selected trial population.
Future work will need prospective confirmation, standardized disease activity assessment, and deeper phenotyping of metabolic therapy, autoantibody profiles, and vascular outcomes. For now, the most defensible conclusion is modest but clinically relevant: in Sjögren’s disease, diabetes appears to identify a subgroup with a heavier cardiometabolic load and a less B-cell–dominant serologic signature, while age and hypertension remain the main drivers of cardiovascular history.